US approval of Brintellix first for Lundbeck/Takeda alliance
This article was originally published in Scrip
Executive Summary
The US FDA has granted the first approval worldwide to Lundbeck's Brintellix (vortioxetine) as a treatment for adults with major depressive disorder, paving the way for the multi-modal therapy to become the first commercial product under the Danish firm's strategic alliance with Takeda.